Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KR232
- Development stage
- Preclinical
- Lead developer
- Qingfeng Pharmaceutical Group
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
KR232 is an investigational drug candidate currently in the IND-enabling phase of development at Jiangxi Kvvit Pharmaceutical (also known as Qingfeng Pharmaceutical Group). Positioned within the company's Central Nervous System (CNS) therapeutic pipeline, KR232 is an internal research asset that has progressed past the preclinical candidate (PCC) stage. While the specific biological target and mechanism of action have not been publicly disclosed, the candidate is part of a portfolio of small molecules being developed for neurological or psychiatric indications. The drug is currently undergoing studies to support an Investigational New Drug (IND) application for entry into clinical trials.
Beyond the preview
Go deeper on KR232.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KR232.